A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer-Reference-Cited by-同舟云学术

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer

Published:2017-03-31 Issue:6 Volume:7 Page:610-619
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

van Geel Robin M.J.M.,Tabernero Josep,Elez Elena,Bendell Johanna C.,Spreafico Anna,Schuler Martin,Yoshino Takayuki,Delord Jean-Pierre,Yamada Yasuhide,Lolkema Martijn P.,Faris Jason E.,Eskens Ferry A.L.M.,Sharma Sunil,Yaeger Rona,Lenz Heinz-Josef,Wainberg Zev A.,Avsar Emin,Chatterjee Arkendu,Jaeger Savina,Tan Eugene,Maharry Kati,Demuth Tim,Schellens Jan H.M.

Funder

German Cancer Consortium

EU Seventh Framework Programme

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 203 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications;Seminars in Cancer Biology;2024-11

2. SIRT1: a novel regulator in colorectal cancer;Biomedicine & Pharmacotherapy;2024-09

3. BRAF-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities;Clinical Colorectal Cancer;2024-09

4. Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors;Frontiers in Oncology;2024-07-12

5. A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance;Nature Cancer;2024-07-11